Alocril
| Alocril | |
|---|---|
| DOSAGE | 1-2 gtts BID |
| Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent. | |
| GENERIC | nedocromil sodium 2.0% |
| SIZE | 5mL |
| INDICATIONS | ALOCRIL® ophthalmic solution is indicated for the treatment of itching associated with allergic conjunctivitis. |
| MECHANISM OF ACTION | Mast Cell Stabilizer (2nd generation) |
| MICROBIOLOGY | Nedocromil sodium inhibits the release of mediators from cells involved in hypersensitivity reactions. Decreased chemotaxis and decreased activation of eosinophils have also been demonstrated. Als inhibits histamine release from a population of mast cells having been defined as belonging to the mucosal sub type and inhibits beta-glucuronidase release from macrophages. |
| CONTRAINDICATIONS & WARNINGS | ALOCRIL® ophthalmic solution is contraindicated in those patients who have shown hypersensitivity to nedocromil sodium or to any of the other ingredients. |
| PEDIATRIC USE | Safety and effectiveness in children below the age of 3 years have not been established. |
| PREGNANCY | Category B Teratogenic Effects Reproduction studies performed in mice, rats and rabbits using a subcutaneous dose of 100 mg/kg/day (more than 1600 times the maximum human daily ocular dose on a mg/kg basis) revealed no evidence of teratogenicity or harm to the fetus due to nedocromil sodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ALOCRIL® ophthalmic solution should be used during pregnancy only if clearly needed. |
| NOTE | Requires a week or two for effect. Sometimes used to reduce contact lens intolerance. |